Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 28, 2026
DataAggregated Company Financials
Companies66
  • 7D10.3%
  • 3M17.4%
  • 1Y17.6%
  • YTD-6.7%

Over the last 7 days, the Life Sciences industry has risen 10%, driven by gains from Thermo Fisher Scientific of 10%. During this same period, the Veraxa Biotech underperformed, falling 48%. This means that the industry has gained 18% over the past year. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 29 Jun 2026US$635.6bUS$151.2bUS$13.6b43.9x46.6x4.2x
Wed, 27 May 2026US$544.2bUS$150.3bUS$14.0b33.3x38.9x3.6x
Fri, 24 Apr 2026US$580.6bUS$148.1bUS$14.2b30.8x41x3.9x
Sun, 22 Mar 2026US$542.7bUS$147.8bUS$14.0b34.6x38.7x3.7x
Tue, 17 Feb 2026US$589.2bUS$147.7bUS$13.9b35.2x42.4x4x
Thu, 15 Jan 2026US$693.6bUS$145.8bUS$12.4b38.1x56.1x4.8x
Sat, 13 Dec 2025US$668.3bUS$145.8bUS$12.5b34.4x53.6x4.6x
Mon, 10 Nov 2025US$636.4bUS$145.7bUS$12.2b34.1x52.3x4.4x
Wed, 08 Oct 2025US$631.1bUS$144.3bUS$14.6b32.2x43.4x4.4x
Fri, 05 Sep 2025US$572.4bUS$144.3bUS$14.6b29.9x39.3x4x
Sun, 03 Aug 2025US$552.8bUS$143.9bUS$13.0b31.8x42.5x3.8x
Tue, 01 Jul 2025US$531.9bUS$142.9bUS$9.1b35.6x58.3x3.7x
Thu, 29 May 2025US$507.9bUS$142.8bUS$9.1b32.5x55.9x3.6x
Sat, 26 Apr 2025US$523.1bUS$142.6bUS$10.0b37.5x52.4x3.7x
Mon, 24 Mar 2025US$596.0bUS$143.0bUS$9.9b38.7x60.2x4.2x
Wed, 19 Feb 2025US$619.7bUS$143.3bUS$10.0b35x62x4.3x
Fri, 17 Jan 2025US$674.9bUS$142.4bUS$10.2b44.4x66.1x4.7x
Sun, 15 Dec 2024US$666.2bUS$142.4bUS$10.2b45.5x65.2x4.7x
Tue, 12 Nov 2024US$696.6bUS$142.4bUS$10.3b43.4x67.7x4.9x
Thu, 10 Oct 2024US$726.9bUS$141.8bUS$8.5b37x85.6x5.1x
Sat, 07 Sep 2024US$731.3bUS$141.8bUS$8.5b37.5x86.1x5.2x
Mon, 05 Aug 2024US$741.1bUS$140.9bUS$11.3b37.3x65.8x5.3x
Wed, 03 Jul 2024US$668.7bUS$141.3bUS$12.2b38.5x54.9x4.7x
Fri, 31 May 2024US$696.4bUS$141.3bUS$12.4b38.2x56x4.9x
Sun, 28 Apr 2024US$709.6bUS$141.6bUS$12.7b39.2x55.8x5x
Tue, 26 Mar 2024US$749.2bUS$142.1bUS$12.8b43.8x58.4x5.3x
Thu, 22 Feb 2024US$714.0bUS$142.2bUS$12.5b43.1x57x5x
Sat, 20 Jan 2024US$687.1bUS$153.8bUS$14.2b35.9x48.5x4.5x
Mon, 18 Dec 2023US$684.6bUS$153.7bUS$14.2b37.1x48.1x4.5x
Wed, 15 Nov 2023US$581.7bUS$153.9bUS$13.9b32.8x41.9x3.8x
Fri, 13 Oct 2023US$646.8bUS$154.6bUS$11.2b33x57.7x4.2x
Sun, 10 Sep 2023US$687.1bUS$154.6bUS$11.2b31.6x61.3x4.4x
Tue, 08 Aug 2023US$726.9bUS$154.7bUS$11.3b30.3x64.6x4.7x
Thu, 06 Jul 2023US$694.7bUS$152.4bUS$12.5b29.5x55.6x4.6x
Price to Earnings Ratio

55.6x


Total Market Cap: US$694.7bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 46.6x which is lower than its 3-year average PE of 56.1x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 2.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-2.52%
Healthcare7.49%
Life Sciences10.33%
Clinical Research and Equipment10.33%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$513.0310.4%
+US$18.0b		25.7%PE27.8x
DHR DanaherUS$196.1910.7%
+US$13.5b		-1.3%PE37.8x
IQV IQVIA HoldingsUS$191.1413.9%
+US$3.9b		21.4%PE23x
A Agilent TechnologiesUS$136.017.0%
+US$2.5b		14.1%PE27.2x
MTD Mettler-Toledo InternationalUS$1.26k10.4%
+US$2.4b		6.7%PE29.2x

Latest News

TECH
US$71.00
Bio-Techne
7D
22.5%
1Y
37.0%
A
US$136.01
Agilent Technologies
7D
7.0%
1Y
14.1%
TMO
US$513.03
Thermo Fisher Scientific
7D
10.4%
1Y
25.7%
DHR
US$196.19
Danaher
7D
10.7%
1Y
-1.3%
Narrative Update • Jun 26

DHR: Bioprocess Recovery And Masimo Integration Will Support Premium Multiple

Danaher’s analyst price target has been reduced by about $5 to $242, as analysts factor in a slightly higher discount rate, a more conservative profit margin, and updated views on life science tools demand that balance cautious sector sentiment with selective signs of recovery. Analyst Commentary Recent research around Danaher points to a mixed setup, with some analysts focusing on recovery potential in life science tools and bioprocessing, and others highlighting valuation questions and business complexity.
LFCR
US$5.17
Lifecore Biomedical
7D
-6.7%
1Y
-36.9%
Narrative Update • Jun 26

LFCR: New Pharma Agreements Will Shape A Measured Outlook Ahead

Lifecore Biomedical’s analyst price target has moved to $6.50, a $0.50 increase that analysts link to recent agreements with global pharmaceutical partners, as well as greater confidence in the company’s ability to expand its clinical reach and execute on its plans. Analyst Commentary Recent Street research on Lifecore Biomedical centers on the updated US$6.50 price target, which is tied to new agreements with global pharmaceutical partners and increased confidence in the company’s ability to carry out its plans.
QSI
US$0.85
Quantum-Si
7D
-14.4%
1Y
-56.2%
Narrative Update • Jun 26

QSI: Partnership Progress Will Support Future Single Molecule Sequencing Adoption

Analysts have cut their price target for Quantum-Si, citing updated assumptions that reflect a fair value of $1.00, a higher discount rate of 7.91%, much stronger modeled revenue growth of 138.19%, a slightly adjusted profit margin of 15.57%, and a reduced future P/E of 85.78x. What’s in the News for Quantum-Si Quantum-Si announced a partnership with Cell Signaling Technology to combine post-translational modification detection and immunoaffinity enrichment expertise with Quantum-Si’s Proteus single-molecule protein sequencing workflows for research use.
ILMN
US$176.55
Illumina
7D
9.0%
1Y
86.3%
SEER
US$1.66
Seer
7D
-4.6%
1Y
-21.7%
Narrative Update • Jun 22

SEER: Activist Bid And Buybacks Will Test Bullish Repricing Thesis

Analysts have raised their price target on Seer to $4.00, citing updated assumptions for higher revenue growth, a modestly higher discount rate, and a lower future P/E multiple as the key drivers of this revised view. What’s in the News for Seer Bradley L.
MTD
US$1,263.75
Mettler-Toledo International
7D
10.4%
1Y
6.7%
Analysis Article • Jun 20

Mettler Toledo International (MTD) Stock Could Be 13.8% Undervalued After Earnings Beat

Fresh quarterly results and ownership trends have pushed Mettler-Toledo International (MTD) into focus after the company reported earnings that beat market expectations and year-over-year growth in both revenue and net profit. See our latest analysis for Mettler-Toledo International. Despite the upbeat earnings surprise and higher institutional ownership, Mettler-Toledo International’s 1-month share price return of 4.99% comes after the stock fell 18.89% year to date and its 1-year total...
VRXA
US$2.32
Veraxa Biotech
7D
-48.2%
1Y
-77.7%
LAB
US$0.73
Standard BioTools
7D
-11.5%
1Y
-38.3%
Narrative Update • Jun 18

LAB: Merger With Treeline And 2026 Guidance Will Support Upside

Analysts have kept their average price target for Standard BioTools unchanged at $1.35. This steadiness reflects updated assumptions that now include a slightly higher discount rate, a smaller projected revenue decline, a largely similar profit margin outlook, and a marginally higher future P/E multiple.
MEDP
US$527.07
Medpace Holdings
7D
14.5%
1Y
69.6%
IQV
US$191.14
IQVIA Holdings
7D
13.9%
1Y
21.4%
Narrative Update • Jun 14

IQV: AI Initiatives And B2B Demand Will Support Earnings Reacceleration

IQVIA Holdings' implied fair value has been trimmed by about $1.65 to roughly $226.95, reflecting analysts' lower price targets around $210 in response to cautious sentiment on life science tools, even as they see early signs of recovery in areas like bioprocessing and quality assurance. Analyst Commentary Recent research points to a mixed setup for IQVIA Holdings, where cautious sentiment on life science tools is bumping up against early signs of recovery in specific end markets.
CDT
US$0.64
CDT Equity
7D
-37.6%
1Y
-99.9%
CDXS
US$2.39
Codexis
7D
-7.0%
1Y
0%
NAUT
US$2.00
Nautilus Biotechnology
7D
-12.3%
1Y
188.3%